Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Cutler, Corey  [Clear All Filters]
Journal Article
Gandelman JS, Zic J, Dewan AK, Lee SJ, Flowers M, Cutler C, Pidala J, Chen H, Jagasia MH, Tkaczyk ER. The Anatomic Distribution of Skin Involvement in Patients with Incident Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2018.
Pidala JA, Hamilton BK, Martin PJ, Onstad L, Storer BE, Palmer J, Alousi A, Cutler C, Jagasia MH, Chen GL, et al. The Chronic Graft-vs.-Host Disease Failure-Free Survival (cGVHD-FFS) index. Biol Blood Marrow Transplant. 2019.
Forcade E, Kim HT, Cutler C, Wang K, Alho AC, Nikiforow S, Ho VT, Koreth J, Armand P, Alyea EP, et al. Circulating T follicular helper cells with increased function during chronic graft-versus-host-disease. Blood. 2016.
Atallah E, Logan B, Chen M, Cutler C, Deeg J, Jacoby M, Champlin R, Nishihori T, Confer D, Gajewski J, et al. Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome: The Medicare Coverage With Evidence Development Study. JAMA Oncol. 2019.
Amonoo HL, Markovitz NH, P Johnson C, Kwok A, Dale C, Deary EC, Daskalakis E, Choe JJ, Yamin N, Gothoskar M, et al. Delirium and Healthcare Utilization in Patients Undergoing Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2023.
Dean D, Lee SJ, Cutler C, Gooley TA, Hujoel P, Oh UYuri, Bennett-Johnson L, Hagstrom MK, Rothen M, Lloid M, et al. Dental evaluation and clearance prior to allogeneic hematopoietic cell transplantation. Oral Dis. 2023.
Koreth J, Kim HT, Nikiforow S, Milford EL, Armand P, Cutler C, Glotzbecker B, Ho VT, Antin JH, Soiffer RJ, et al. Donor Chimerism Early after Reduced-intensity Conditioning Hematopoietic Stem Cell Transplantation Predicts Relapse and Survival. Biol Blood Marrow Transplant. 2014.
Roeker LE, Kim HT, Glotzbecker B, Nageshwar P, Nikiforow S, Koreth J, Armand P, Cutler C, Alyea EP, Antin JH, et al. Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018.
Palmer J, Chai X, Martin PJ, Weisdorf D, Inamoto Y, Pidala J, Jagasia M, Pavletic S, Cutler C, Vogelsang G, et al. Failure-free Survival in a Prospective Cohort of Patients with Chronic Graft-Versus-Host Disease. Haematologica. 2015.
Gray TF, Do KM, Amonoo HL, Sullivan L, Kelkar A, Pirl W, Hammer M, Tulsky JA, El-Jawahri A, Cutler C, et al. Family Caregiver Experiences in the Inpatient and Outpatient Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation Settings: A Qualitative Study. Transplant Cell Ther. 2023.
Amonoo HL, Daskalakis E, Deary EC, Celano CM, Ghanime PMaria, Healy BC, Cutler C, Pirl WF, Park ER, Gudenkauf LM, et al. Feasibility of a positive psychology intervention (PATH) in allogeneic hematopoietic stem cell transplantation survivors: Randomized pilot trial design and methods. Contemp Clin Trials. 2023:107272.
Newell LF, DeFor TE, Cutler C, Verneris MR, Blazar BR, Miller JS, Antin JH, Howard A, Wu J, MacMillan ML, et al. Follistatin and Soluble Endoglin Predict 1-year Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplant. Biol Blood Marrow Transplant. 2019.
Lin C, Sajeev G, Stiff PJ, Brunstein CG, Cutler C, Sanz G, Lindemans CA, Rezvani AR, Hanna R, Koh LPiu, et al. Health-Related Quality of Life Following Allogeneic Hematopoietic Cell Transplantation with Omidubicel Versus Umbilical Cord Blood. Transplant Cell Ther. 2022.
DeFilipp Z, Ciurea SO, Cutler C, Robin M, Warlick ED, Nakamura R, Brunner AM, Dholaria B, Walker AR, Kröger N, et al. Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the ASTCT Committee on Practice Guidelines. Transplant Cell Ther. 2022.
Sekeres MA, Cutler C. How we treat higher-risk myelodysplastic syndromes. Blood. 2013.
Waller EK, Miklos D, Cutler C, Arora M, Jagasia MH, Pusic I, Flowers MED, Logan AC, Nakamura R, Chang S, et al. Ibrutinib for Chronic Graft-Versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study. Biol Blood Marrow Transplant. 2019.
Chin K-K, Kim HT, Inyang E-A, Ho V, Koreth J, Romee R, Gooptu M, Shapiro R, Antin J, Soiffer R, et al. Ibrutinib in Steroid-Refractory Chronic Graft-Versus-Host Disease, a Single-Center Experience. Transplant Cell Ther. 2021.
Dubovsky JA, Flynn R, Du J, Harrington BK, Zhong Y, Kaffenberger B, Yang C, Towns WH, Lehman A, Johnson AJ, et al. Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J Clin Invest. 2014.
Murase K, Kim HT, Bascug ORGregory, Kawano Y, Ryan J, Matsuoka K-I, Davids MS, Koreth J, Ho VT, Cutler C, et al. Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation. Haematologica. 2014.
Davids MS, Kim HT, Bachireddy P, Costello C, Liguori R, Savell A, Lukez AP, Avigan D, Bin Chen Y-, McSweeney P, et al. Ipilimumab for Patients with Relapse after Allogeneic Transplantation. N Engl J Med. 2016;375(2):143-153.
Amonoo HL, Deary EC, Wang A, Newcomb RA, Daskalakis E, Weber D, Holmbeck KE, Choe JJ, Nabily A, Cutler C, et al. Medication Adherence in Patients with Hematologic Malignancies who are Hematopoietic Stem Cell Transplantation Survivors: A Qualitative Study. Transplant Cell Ther. 2023.
Lin C, Schwarzbach A, Sanz J, Montesinos P, Stiff P, Parikh S, Brunstein C, Cutler C, Lindemans CA, Hanna R, et al. Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials. Transplant Cell Ther. 2023.
Pidala J, Kitko C, Lee SJ, Carpenter P, Cuvelier GDE, Holtan S, Flowers MED, Cutler C, Jagasia M, Gooley T, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report. Transplant Cell Ther. 2021.
Im A, Pusic I, Onstad L, Kitko CL, Hamilton BK, Alousi AM, Flowers ME, Sarantopoulos S, Carpenter P, White J, et al. Patient-reported treatment response in chronic graft--host disease. Haematologica. 2023.
Dong J, Buradagunta CStaffi, Zhang T, Spellman S, Bolon Y-T, DeZern AE, Gadalla SM, H Deeg J, Nazha A, Cutler C, et al. Prognostic landscape of mitochondrial genome in myelodysplastic syndrome after stem-cell transplantation. J Hematol Oncol. 2023;16(1):21.

Pages